You are here

Article Text

Article menu
Download PDFPDF
Pharmacokinetics and pharmacodynamics
PKP-019 Experience of once daily tacrolimus individualised dosing through a bayesian approach in de novo liver transplant recipients
  1. P Más-Serrano1,
  2. ML Boquera Ferrer1,
  3. R Nalda-Molina2,
  4. M Díaz González1,
  5. G Rodríguez-Laiz3,
  6. P Melgar3,
  7. M Rodríguez Soler4,
  8. F Carnicer4,
  9. F Lluis3,
  10. J Selva Otaolaurruchi1
  1. 1General University Hospital of Alicante, Clinical Pharmacokinetic Unit, Department of Pharmacy, Alicante, Spain
  2. 2University of Miguel Hernandez, Engineering-Pharmacy and Pharmaceutics Division, San Juan de Alicante, Spain
  3. 3General University Hospital of Alicante, Hepatobiliary Surgery and Liver Transplantation Unit, Department of General Surgery, Alicante, Spain
  4. 4General University Hospital of Alicante, Hepatology Unit, Alicante, Spain

Abstract

Background A triple regimen with tacrolimus constitutes the basis of immunosuppressive protocols after orthotopic liver transplantation (OLT).

Purpose The aim was to analyse the efficacy and safety of once daily tacrolimus (TAC-OD) (Advagraf) individualised dosing through a Bayesian approach in de novo OLT patients.

Material and methods This was a retrospective study (September 2012–April 2016). Inclusion criteria: adult OLT patients with a minimum follow-up of 7 days. Immunosuppressive protocol: TAC-OD (first dose: 0.15 mg/kg/day), mycophenolate mofetil (1 g/24 hours orally) and steroids within the first 24 hours after OLT. Patients with renal dysfunction were treated with interleukin-2 receptor antagonists and tacrolimus was delayed. Blood trough levels of tacrolimus were monitored every 24 hours during hospitalisation and every outpatient visit. Dose adjustments were performed with every blood withdrawn through calculation of the empirical Bayesian estimates of the pharmacokinetic parameters. Population pharmacokinetics models were implemented in NONMEM V.7.3. Tacrolimus target trough levels were 8–10 ng/mL during the first month, reducing progressively to 5–8 ng/mL. Efficacy variables: tacrolimus trough levels, hospital stay and survival. Safety variables: serum creatinine (SCr).

Results 2515 concentrations were collected from 99 patients (83 men/16 women). Mean age was 57.0 years (95% CI 53.9–60.14), IMC 16.07±4.7 kg/m2 and MELD 15 (95% CI 12–18). Median (p25–p75) trough concentrations (ng/mL) of tacrolimus were 8.9 (5.3–11.6), 7.5 (5.4–9.7), 8.78 (6.9–10.65) and 9.7 (8.17–11.9) at 2, 7, 15 and 30 days, and 8.43 (7.38–10.02), 7.9 (6.45–9.04), 7.53 (6–9.17), 7.22 (6–8.7), 6.37 (5–7.25), 6.1 (5.2–7.48), 4.4 (3.8–6.35) and 4.5 (4–5.3) at 2, 3, 6, 12, 18, 24, 36 and 42 months after transplantation (statistically significant decrease after the second month, p<0.05). Basal mean SCr was 1.11 mg/dL (95% CI 1.17–1.45) and it remained stable after 7 days of OLT (SCr 0.98 mg/dL; 95% CI 0.8–1.36) until 4 years (1.11 mg/dL; 95% CI 0.99–1.24) (p>0.05). Median hospital stay after transplantation was 4 days (p25–p75: 3–6). Patient survival at 1, 3 and 4 years was 85%, 83.4% and 79.6%, respectively. Mean time of survival was 41 months (95% CI 37.6–44.4).

Conclusion Our dosing protocol of TAC-OD based on Bayesian methodology was feasible in routine clinical practice, the target concentration was achieved at 48 hours in 75% of patients and it showed favourable outcomes in terms of survival and safety.

No conflict of interest

https://doi.org/10.1136/ejhpharm-2017-000640.447

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.